CHICAGO, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the 2014 RBC Capital Markets' Global Healthcare Conference in New York on Tuesday, February 25, 2014 at 11:30 am EST.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.
Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
CONTACT: Allison Wey Durata Therapeutics, Inc. Vice President, Investor Relations and Public Affairs (312) 219-7017 firstname.lastname@example.org
Source:Durata Therapeutics, Inc.